FDA panel votes to expand use of Vertex cystic fibrosis drug
October 21, 2014 at 17:41 PM EDT
Oct 21 (Reuters) - A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a wider range of patients with the rare lung disease, the company said.
